

## METHODS

## Combining machine learning with structure-based protein design to predict and engineer post-translational modifications of proteins

Moritz Ertelt<sup>1,2</sup>, Vikram Khipple Mulligan<sup>3</sup>, Jack B. Maguire<sup>4</sup>, Sergey Lyskov<sup>5</sup>, Rocco Moretti<sup>6,7</sup>, Torben Schiffner<sup>1</sup>, Jens Meiler<sup>1,2,6,7</sup>, Clara T. Schoeder<sup>1,2\*</sup>

**1** Institute for Drug Discovery, Leipzig University Medical Faculty, Leipzig, Germany, **2** Center for Scalable Data Analytics and Artificial Intelligence ScaDS.AI, Dresden/Leipzig, Germany, **3** Center for Computational Biology, Flatiron Institute, New York, New York, United States of America, **4** Program in Bioinformatics and Computational Biology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, **5** Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland, United States of America, **6** Department of Chemistry, Vanderbilt University, Nashville, Tennessee, United States of America, **7** Center for Structural Biology, Vanderbilt University, Nashville, Tennessee, United States of America

\* [clara.schoeder@medizin.uni-leipzig.de](mailto:clara.schoeder@medizin.uni-leipzig.de)



## OPEN ACCESS

**Citation:** Ertelt M, Mulligan VK, Maguire JB, Lyskov S, Moretti R, Schiffner T, et al. (2024) Combining machine learning with structure-based protein design to predict and engineer post-translational modifications of proteins. *PLoS Comput Biol* 20(3): e1011939. <https://doi.org/10.1371/journal.pcbi.1011939>

**Editor:** Joanna Slusky, University of Kansas, UNITED STATES

**Received:** June 18, 2023

**Accepted:** February 20, 2024

**Published:** March 14, 2024

**Copyright:** © 2024 Ertelt et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All data and code used for running experiments, model training, and plotting is available on a GitHub repository at <https://github.com/meilerlab/PTMPrediction>. Additional documentation for the Rosetta SimpleMetric can be found at [https://www.rosettacommons.org/docs/latest/scripting\\_documentation/RosettaScripts/SimpleMetrics/simple\\_metric\\_pages/PTMPredictionMetric](https://www.rosettacommons.org/docs/latest/scripting_documentation/RosettaScripts/SimpleMetrics/simple_metric_pages/PTMPredictionMetric).

## Abstract

Post-translational modifications (PTMs) of proteins play a vital role in their function and stability. These modifications influence protein folding, signaling, protein-protein interactions, enzyme activity, binding affinity, aggregation, degradation, and much more. To date, over 400 types of PTMs have been described, representing chemical diversity well beyond the genetically encoded amino acids. Such modifications pose a challenge to the successful design of proteins, but also represent a major opportunity to diversify the protein engineering toolbox. To this end, we first trained artificial neural networks (ANNs) to predict eighteen of the most abundant PTMs, including protein glycosylation, phosphorylation, methylation, and deamidation. In a second step, these models were implemented inside the computational protein modeling suite Rosetta, which allows flexible combination with existing protocols to model the modified sites and understand their impact on protein stability as well as function. Lastly, we developed a new design protocol that either maximizes or minimizes the predicted probability of a particular site being modified. We find that this combination of ANN prediction and structure-based design can enable the modification of existing, as well as the introduction of novel, PTMs. The potential applications of our work include, but are not limited to, glycan masking of epitopes, strengthening protein-protein interactions through phosphorylation, as well as protecting proteins from deamidation liabilities. These applications are especially important for the design of new protein therapeutics where PTMs can drastically change the therapeutic properties of a protein. Our work adds novel tools to Rosetta's protein engineering toolbox that allow for the rational design of PTMs.

**Funding:** This work is supported through a Rosetta mini-grant under award number RC22021 from RosettaCommons ([www.rosettacommons.org](http://www.rosettacommons.org)) held by CTS. ME, JM and CTS acknowledge the financial support by the Federal Ministry of Education and Research of Germany and by the Sächsische Staatsministerium für Wissenschaft Kultur und Tourismus in the program Center of Excellence for AI-research "Center for Scalable Data Analytics and Artificial Intelligence Dresden/Leipzig", project identification number: ScaDS.AI (<https://scads.ai/>). ME's position is funded through an award by ScaDS.AI. VKM is supported by the Simons Foundation (<https://www.simonsfoundation.org/>). TS is supported by a Sofja Kovalevskaja prize from the Alexander-von-Humboldt foundation (<https://www.humboldt-foundation.de/>), while JM is supported by an Alexander-von-Humboldt professorship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** The authors have declared that no competing interests exist.

## Author summary

Machine learning is changing the world of protein design, from structure prediction methods like AlphaFold to fixed-backbone design methods like ProteinMPNN. Machine learning methods have made much progress in various aspects of protein computational biology, both complementing and, in some cases, surpassing traditional macromolecular modeling methods such as those combined in libraries like the Rosetta software suite. However, a lack of compatibility and flexibility can hinder interoperability with existing methods, preventing the full potential of these new solutions from being realized. Here, we first present a new machine learning tool for predicting post-translational modifications (PTMs), which play an important role in the stability and function of proteins, and then highlight how the implementation of this tool in the existing Rosetta toolbox can facilitate new applications. To this end, we combine PTM prediction with protein design, maximizing or minimizing the predicted probability of a post-translational modification occurring at a specific site. As one example, we predict the *N*-linked glycosylation of influenza hemagglutinin, which has applications in both understanding the evolution of viral strains over time, and engineering additional glycosylation sites to mask unwanted epitopes of vaccine candidates.

This is a *PLOS Computational Biology Methods* paper.

## Introduction

PTMs play an important role in modulating both protein stability and many aspects of protein function. PTMs can be divided into reversible and irreversible modifications, with some modifications, like *N*-linked glycosylation, even occurring before protein folding. The diversity of possible PTMs highlights the complex chemical composition of proteins, which is not limited to the standard 20 letter amino acid code. Understanding the impact of modifications is especially vital in the field of protein therapeutics, where PTMs can range from being essential for desired therapeutic function, to completely blocking therapeutic function through unforeseen changes in stability and function over time [1].

Glycosylation describes the enzymatic attachment of an oligosaccharide to a protein residue. This generally occurs in the endoplasmic reticulum (ER) and Golgi apparatus for proteins bound for secretion or for cell surface expression, though rare cytoplasmic and nuclear glycoproteins are known [2,3]. Glycosylation is further classified into *N*- and *O*-glycosylation, where the carbohydrate linkage occurs either at the side-chain amide nitrogen of an asparagine residue (*N*-glycosylation), or the hydroxyl oxygen atom of a serine, threonine, or (very rarely) tyrosine residue (*O*-glycosylation). Additionally, *N*-glycosylation occurs in the unfolded state while *O*-glycosylation occurs after the protein is already folded. Both *N*- and *O*-glycosylation tend to increase thermostability and solubility [4], and both can modulate interactions with other proteins [2]. For *N*-glycosylation, there exists a well-known sequence motif: NxT/S, where x is any amino acid except proline [5]. While this sequence motif is helpful in identifying potential sites, the existence of a sequon is not sufficient to guarantee glycosylation. Additionally, multiple improved sequons have been discovered through trial and error, highlighting the complexity beyond the NxT/S motif [6,7]. For *O*-glycosylation a clear sequence motif is not known; however, *O*-glycosylation sites tend to cluster in proline/serine

rich flexible regions of proteins [8]. Glycosylation of protein therapeutics can impact their folding, solubility, thermal stability, chemical stability, and aggregation propensity [9,10,11]. The list of protein drugs affected by glycosylation is long and includes chymotrypsin [12,13], insulin [14], lenograstim [15,16,17], antithrombin [18], agalsidase alfa/beta [19,20,21], and various antibodies [11] (for a detailed review refer to [10]). For this reason, when engineering protein therapeutics, it is essential to be able to predict glycosylation, and extremely useful to be able to rationally design for or against it. This “glycoengineering” can be particularly useful in vaccine development: off-target epitopes, for instance in engineered epitope-presentation scaffolds, can be “masked” by suitable introduction of glycosylation sites [22,23]. Glycans are commonly used by viruses to hide antigenic protein surfaces, however, this mechanism can also be used to prevent unwanted immune reactions in vaccines and direct an immune response to a desired site. For influenza hemagglutinin, for example, the creation of a “hyper-glycosylated” variant through seven additional glycosylation sites lead to better protection against morbidity and mortality in mice upon virus challenge by directing the immune response to a neutralizing epitope left unglycosylated [24].

Deamidation, the spontaneous reaction of asparagine to isoaspartate, is one of the most commonly occurring PTMs known. The resulting modification leads to structural changes through the insertion of a negative charge and through significant alteration of the protein backbone (effectively, replacing an  $\alpha$ -L-amino acid with a  $\beta^3$ -amino acid with the chiral center reversed), affecting both protein stability and function. *In vivo*, deamidation is thought to play the role of a molecular “clock”, marking proteins for degradation through increased susceptibility to proteolysis [25,26,27]. The rate of deamidation is not only influenced by pH and temperature but also by its local environment, including the neighboring residues, secondary structure, and solvent accessibility [28,29]. Therefore, the deamidation half-life of a protein can be as long as several months or as short as hours, at which point it can begin to affect the pharmacokinetics of therapeutic proteins. A commonly described deamidation motif is an asparagine in a flexible loop, followed by a glycine residue [28]. The occurrence of a deamidation site, however, cannot be simply derived from sequence alone and thus remains unpredictable without experimental characterization. For therapeutic proteins the rate of deamidation can strongly influence both shelf life and persistence time in the body, through either loss of function or stability, and therefore render them ineffective [30,31]. Therapeutic proteins affected include, but are not limited to, antibodies [32], vaccine antigens [33,34,35], peptides [36], adeno-associated virus (AAV) serotypes used for human gene therapy [37], human hormones [25,38] and enzymes [25]. In case of AAV vectors, multiple deamidation sites were discovered and engineered for enhanced stability against deamidation, leading to higher transduction efficiencies in mice, as well as different T cell activation profiles [39]. For antibodies, deamidation potentially leads not only to aggregation but also to drastic decreases in antigen binding affinity [32]. Deamidation sites are commonly discovered late in the development process and then corrected by trial-and-error mutation studies, leading to unnecessary costs and liabilities. Although nowadays many companies use computational liability screening methods, most of them are purely sequence-based.

More recently, several studies have used rational design to create proteins responsive to changes in either phosphorylation or glutathionylation with potential applications in building biomaterials or controlling cellular behavior. Scheuermann et al. [40] and Gao et al. [41] designed minimal domains derived from EF-Hand calcium-binding domains that only bind terbium upon glutathionylation or phosphorylation of a key residue, therefore regulating the function of a protein through its modification status. Similarly, Winter et al. [42] and Thompson et al. [43] designed proteins with their multimerization status being defined by whether a particular residue located at the interface is phosphorylated or not. Woodall et al. [44] combine

the two approaches, creating tyrosine and serine kinase-driven protein switches where protein association is controlled by kinase activity, leading to the reconstitution of green fluorescent protein fluorescence or the inhibition of the protease calpain. These seminal studies highlight the potential benefit of PTM-aware protein engineering.

As the occurrence and rate of PTMs is dependent on multiple factors, prediction needs to take many features into account. Previously, multiple studies used machine learning methods to predict PTMs, generally focusing on a single prominent modification. Often, sequence is the only readily available information, and therefore used as the main feature in combination with *in silico* predicted structural features like solvent accessibility or secondary structure. In the case of protein deamidation, for example, a recent study used both sequence and selected structural features, including neighboring residues, solvent accessible surface area (SASA), dihedral angles and half-life times derived from a mass spectrometry poly-peptide study [27]. In the case of *N*-linked glycosylation, multiple studies [45,46,47,48] trained neural networks on the sequence context of glycosylation sites, often using the full-length protein sequence, or leveraging homology-based features. In these cases, it is not entirely clear whether the model learned general sequon preferences or simply protein homology, especially in the case where proteins with cellular localization in the nucleus or no glycosylation sequon were used as negative examples. However, the usefulness of a predictive model is not measured alone by its accuracy, but whether the choice of data reflects the downstream task the model is intended to be used for. The approaches do not only differ by the features or neural network architectures used, but crucially by their choice and filtering of data. These filtering steps are especially important to avoid overestimating the performance of a model, because of, for example, missed homology or false negatives. While these models are potentially useful for predicting glycosylation in natural proteins, they are of limited use in the case of (re-)engineering proteins. With the recent revolution in protein structure prediction [49,50], however, structural features are more readily available to complement sequence information. The engineering of modification sites would offer both the reduction of liabilities from unwanted PTMs, as well as the introduction of desirable PTMs in order to improve stability or alter functionality of therapeutics. The protein modeling suite Rosetta [51] has proven successful in tasks such as designing proteins for thermodynamic stability [52] and functionality [53]. By implementing accurate prediction of PTMs using machine learning in Rosetta, we can combine this new tool with Rosetta's existing structure-based protein design toolbox to either screen pools of natural, reengineered, or *de novo* designed proteins for the presence or absence of a PTM, or to impose the presence or absence of a PTM as a requirement during the design process. Moreover, by bringing this into the context of existing protein design protocols, we can combine PTM restrictions or requirements with other design objectives for which well-validated optimization protocols already exist, permitting multi-objective optimization. The integration into the existing Rosetta ecosystem also permits the use of these tools for analytical purposes, to model different modifications in the contexts in which they are likely to occur in order to aid understanding of their impact on protein function and stability. For example, the already present glycosylation modeling tools [54,55,56] allow us to further test the plausibility of a predicted glycosylation site, as well as make predictions about its impact on, for instance, a modelled protein-protein interaction. To our knowledge, no protocol for engineering PTMs which combines machine learning with structure-based design has been implemented yet. We argue that this combination of predictive machine learning methods with structure-based design has great potential for a variety of protein engineering applications [57].

In this study, we implemented both, a metric that scans a given protein structure for predicted PTM sites, as well as a protocol using protein design to either increase or decrease the predicted probability of a modification to occur. Compared to earlier work, we leverage recent


improvements in the field of natural language processing, as well as similarities between modifications, to improve the prediction accuracy. Additionally, the models are implemented as a SimpleMetric [54] (in Rosetta, a module for measuring a property of a structure), allowing seamless integration with other RosettaScripts objects. Internally, the implemented SimpleMetric, called the PTMPredictionMetric, accesses the Tensorflow model through Tensorflow's C API [58]. To ensure robustness, avoid repeated load and initialization of the Tensorflow model, and minimize developer error, we also built a framework, called the RosettaTensorflowManager, for structured C++-style interaction with machine learning models. By implementing these methods in Rosetta, we benefit from existing infrastructure for unit, integration, and scientific testing [59], ensuring that the methods remain functional and that results produced with them remain reproducible. In comparison, Python library compatibilities can be notoriously hard to organize and maintain, hindering reproducibility. A recent study on computational biology webservers found only 31% of them to be consistently working [60].

As a demonstration of our methods, to modify the predicted probability of a modification to occur, we design proteins using a Monte Carlo protocol optimizing the Rosetta score as well as the predicted modification probability. This combination allows us to find a tradeoff between thermodynamic stability and predicted PTM rate. Additionally, given a functionally relevant structure, like an antibody-antigen complex, we can further ensure that the mutation is not disrupting the functionality of a given protein.

## Results

### Collection of sequence and structural data for experimental verified modification sites

In order to train a machine learning model to predict PTMs, we first collected experimentally verified modification sites from the dbPTM [61,62], which provides a non-homologous benchmark dataset with positive and negative sites. In addition to the sequence information, we collected predicted structures for each entry from the AlphaFold2 database [49,50] and filtered them by local as well as overall pLDDT. The resulting structures were used to calculate the SASA, dihedral angles and secondary structure of the modified site and its neighbors using PyRosetta [63] (Fig 1). For most PTMs, an exact sequence motif is not known and therefore the negative examples are not limited to a particular motif. In the case of *N*-linked glycosylation, however, as the NxT/S sequon (where X is any amino acid except proline) is well-described, we decided to focus on predicting whether each asparagine occurring in a sequon is modified, rather than making predictions for all asparagines. To achieve this, we collected structures of eukaryotic proteins produced in eukaryotic expression systems from the protein data bank (PDB) [64] that have at least one sequon with a resolved glycan and searched them for additional sequons that were not glycosylated. To avoid false negatives, we manually screened electron densities to avoid un-assigned glycosylation sites, filtered proteins treated with an endoglycosidase (e.g. PNGase F), as well as cross-checked against the UniProt [65,66] database. This selection resulted in 2115 positive and 355 negative samples for *N*-linked glycosylation (Table C in S1 Text). Lastly, as there was no available benchmark dataset for deamidation, we used the published data from Delmar *et al.* [67] to reproduce a deamidation classifier. Since the full sequences of their training data were not publicized, we could not predict their structure with AlphaFold2 and were instead restricted to published data. The number of available data differs drastically for PTMs, for example, phosphorylation has 61340 datapoints while crotonylation has only 145 in total (Table C in S1 Text). The median over all PTMs was 2327 positive and 3690 negative examples. For all datasets, a sequence window around the potentially modified site, instead of the full sequence, was used to prevent signals such as




**Fig 1. Collection of data and feature calculation.** **A)** For all modifications except *N*-linked glycosylation and deamidation, data were collected from the dbPTM and sequence windows of ten residues before/after the modified site were filtered with CD-HIT to 90% sequence identity. Predicted structural models were downloaded from the AlphaFold2 database and filtered by overall and local pLDDT over 50. PyRosetta was used to calculate dihedral angles, secondary structure, and solvent-accessible-surface-area (SASA). **B)** For *N*-linked glycosylation, structures of eukaryotic proteins produced in a eukaryotic expression system with at least one glycan were collected from the Protein Data Bank (PDB) and sequence windows of ten residues before/after the modified site were filtered with CD-HIT to 90% sequence identity. To avoid false negatives, glycosylation sites were compared to UniProt annotations of experimentally verified glycosylation sites and further manually screened for spurious electron density (potentially representing glycan occupancy) or endoglycosidase treatment, removing any such cases from the dataset. PyRosetta was used to calculate the same set of features as for the other modifications.

<https://doi.org/10.1371/journal.pcbi.1011939.g001>

homology to protein families or cellular localization, as we deemed a model fitted to these signals not practically useful in engineering new modifications.

## Prediction of PTMs using machine learning

To predict the occurrence of PTMs, we first trained a two-track neural network for each modification (Fig 2). One track processed sequence features, and the other processed structural features. The resulting Matthews correlation coefficients (MCC) of the test set ranged from 0.76 for proline hydroxylation to 0.10 for *N*-linked glycosylation (Table 1). As modifications with little or unbalanced data showed worse performance, we hypothesized that these cases would benefit from training a classifier which combines prediction of multiple PTMs. As some modifications shared the same kind of amino acid, however, we were not able to train one model for all 19 modifications simultaneously, as a negative example of a e.g., lysine succinylation modification is not guaranteed to also not be sumoylated. Therefore, we trained a multi-prediction model for each modification including all other unique amino acid modifications (Table 1), excluding PTMs affecting the same kind of amino acid. For example, to predict crotonylation (Lys) a model was trained to simultaneously predict hydroxylation (Pro),  $\gamma$ -carboxyglutamic-acid modification (Glu), arginine methylation (Arg), glutathionylation (Cys), phosphorylation (Ser/Thr) and *N*-linked glycosylation (Asn) but not any other lysine modification. In the case of crotonylation, this increases the training data from just 145 crotonylation examples (23 positive, 122 negative) to 88103 examples (11452 positive, 76651 negative) of different PTMs. Multiple PTMs showed a clear improvement over the single prediction case, for example the MCC of *N*-linked glycosylation increased from 0.1 to 0.2 and the MCC of crotonylation increased from 0.32 to 0.49. Overall, modifications with few data improved the most from the multi-prediction approach. For deamidation, we use the published data by Delmar et al. [67] which does not include full sequences or structures and was not made available upon request. Therefore, we were limited to the original data in our feature set and could not combine it with other PTMs.



**Fig 2. Neural network architecture for predicting post-translational modifications (PTMs).** Starting from a Rosetta pose object representing a protein structure and its attributes, sequence and structural features are calculated by already implemented methods in Rosetta and then input into an artificial neural network (ANN) built using the Keras functional API. **A)** Single PTM classification using an embedded sequence window and structural features as input to two-tracks of fully connected layers. Here, one model is trained for each type of PTM. **B)** Multi PTM classification using the same features but with an additional transformer layer in the sequence track and an additional fully connected layer in the structure track of the network. This model combines PTM types with unique amino acids in training and therefore predicts probabilities for multiple PTMs.

<https://doi.org/10.1371/journal.pcbi.1011939.g002>

All models were trained using the Tensorflow library [58] which offers a broad array of solutions for implementing models in a production setting. The models were converted into Tensorflow graphs that can be loaded and used for inference through the Tensorflow C API that is wrapped in Rosetta by a special RosettaTensorflowManager. This is described in detail in **S1 Text**.

After training the prediction classifiers and integrating them in the Rosetta suite, we set out to combine the prediction with protein design to influence the predicted probability of a modification occurring at a given site. To demonstrate this, we chose  $N$ -linked glycosylation and deamidation as examples of either preventing or introducing a particular PTM using protein design.

## Predicting deamidation propensity of Protein A mutations using structure-based design

As the first example we set out to predict the deamidation rate of asparagine residues in immunoglobulin G binding protein A (PDB ID: 1DEE [68]). Protein A is commonly used to purify antibodies and multiple mutations were introduced to increase the stability and prevent deamidation of the residues N23 and N28 [69] (Fig 3A). We correctly predict the deamidation propensity of five out of six asparagines, with N23 showing an increased probability for

Table 1. Different model performances on post-translational modifications.

PTM	AA type	MCC single	MCC multi	AUC single	AUC multi	FP single	FP multi	FN single	FN multi
Hydroxylation	P	<b>0.76</b>	0.75	<b>0.96</b>	0.88	<b>0.08</b>	0.12	<b>0.16</b>	0.12
$\gamma$ -carboxyglutamic-acid	E	0.53	<b>0.67</b>	0.85	<b>0.83</b>	0.27	<b>0.17</b>	0.21	<b>0.17</b>
Deamidation	N	<b>0.54</b>	NA	<b>0.85</b>	NA	<b>0.09</b>	NA	<b>0.31</b>	NA
Lys Methylation	K	0.41	<b>0.41</b>	0.78	<b>0.70</b>	0.27	<b>0.22</b>	0.31	<b>0.37</b>
Malonylation	K	<b>0.37</b>	0.30	<b>0.75</b>	0.65	<b>0.29</b>	0.34	<b>0.33</b>	0.36
Arg Methylation	R	0.37	<b>0.40</b>	0.79	<b>0.71</b>	0.23	<b>0.16</b>	0.36	<b>0.43</b>
Crotonylation	K	0.32	<b>0.49</b>	0.77	<b>0.74</b>	<b>0.48</b>	<b>0.44</b>	0.17	<b>0.08</b>
Ubiquitination	K	<b>0.31</b>	0.26	<b>0.72</b>	0.63	<b>0.36</b>	0.37	<b>0.32</b>	0.37
Succinylation	K	<b>0.31</b>	0.22	<b>0.71</b>	0.61	<b>0.39</b>	0.39	<b>0.30</b>	0.40
Glutathionylation	C	<b>0.30</b>	0.20	<b>0.70</b>	0.60	<b>0.40</b>	0.44	<b>0.30</b>	0.36
Sumoylation	K	0.30	<b>0.30</b>	0.76	<b>0.66</b>	0.32	<b>0.22</b>	0.30	<b>0.45</b>
S-Nitrosylation	C	<b>0.28</b>	0.17	<b>0.70</b>	0.58	<b>0.40</b>	0.34	<b>0.31</b>	0.50
Acetylation	K	<b>0.22</b>	0.22	<b>0.68</b>	0.62	<b>0.44</b>	<b>0.49</b>	<b>0.31</b>	0.28
O-linked Glycosylation	S/T	0.21	<b>0.27</b>	0.75	<b>0.72</b>	0.22	<b>0.20</b>	0.42	<b>0.35</b>
Phosphorylation	S/T	0.17	<b>0.24</b>	0.76	<b>0.72</b>	0.28	<b>0.16</b>	0.34	<b>0.39</b>
Glutarylation	K	0.12	<b>0.18</b>	0.58	<b>0.60</b>	0.45	<b>0.45</b>	0.42	<b>0.35</b>
Citrullination	R	0.10	<b>0.12</b>	0.56	<b>0.61</b>	0.13	<b>0.20</b>	<b>0.74</b>	<b>0.58</b>
N-linked Glycosylation	N	0.10	<b>0.20</b>	0.57	<b>0.62</b>	0.49	<b>0.50</b>	0.37	<b>0.25</b>

Better performing model in bold; AA, Amino Acid; MCC, Matthew's correlation coefficient; AUC, Area under the curve of the receiver operating characteristic curve; FP, False Positive rate; FN, False Negative rate


<https://doi.org/10.1371/journal.pcbi.1011939.t001>

deamidation but below our classification threshold (Fig 3B). The position after the asparagine residue is crucial for the deamidation probability, therefore, we used Rosetta to mutate this position to all possible amino acids except cysteine and compared their newly predicted probability to experimental data (Fig 3C and 3D). For N23 almost all n+1 mutations led to a worse Rosetta energy score and only five out of 19 led to a similar or lower predicted deamidation rate. In the case of N23 all n+1 mutations led to a decrease in predicted deamidation probability and all mutations except for proline had a better Rosetta energy score. This demonstrates that our method can be used to correctly identify deamidation sites and subsequently redesign them to sequences with reduced probabilities. A detailed capture of the protocol can be found at [github.com/MeilerLab/PTMPrediction](https://github.com/MeilerLab/PTMPrediction).

### Predicting glycosylation sites in Influenza hemagglutinin (HA) using structure-based analysis

As second example, we analyzed the possible occurrence of N-linked glycosylation sites in the H3N2 HA protein in different strains of influenza. Since the H3N2 Hong Kong 1968 (HK68) strain, Influenza gained multiple additional glycosylation sites which were experimentally validated to be occupied [70,71,72,73] (Fig 4A). Since glycans are added by the host's cellular machinery, glycosylation facilitates viral evasion of the host immune system. For this reason, it is important to be able to predict glycosylation sites reliably to understand the function of new viral strains. We first predicted the original glycosylation sites using the structure of H3N2 HK68 (PDB ID: 4FNK [71]), correctly classifying four of the five sites. Next, we used Rosetta's mutagenesis tools to introduce the later acquired glycosylation sequons, as well as residues two positions before or after, into the original HK68 structure and predicted their glycosylation probability. Of these four glycosylation sites, we correctly






**Fig 3. Using structure-based design to predict deamidation rates of Protein A mutations.** A). Overview of the Protein A structure (PDB ID: 1DEE) with susceptible deamidation sites colored in red and not susceptible asparagines colored in blue. B) Predicted deamidation probabilities for all asparagine residues in Protein A colored by known susceptibility. The prediction threshold of 0.5 is shown as a gray dotted line. C-D) Predicted deamidation probabilities for mutations of residue following (n+1) the asparagine residues N23/N28 compared to the predicted stability as Rosetta energy units (where more negative equals more stable). The prediction threshold of 0.5 is shown as a gray dotted horizontal line, the vertical line identifies the total score of the native amino acid which is marked by a red circle.

<https://doi.org/10.1371/journal.pcbi.1011939.g003>

predicted three (Fig 4B). This demonstrates that we can identify *N*-linked glycosylation in a structurally heterogeneous protein from modeled structures and that our method captures the evolved glycosylation sites of HA.

### Combining machine learning predictions with structure-based design to optimize the predicted phosphorylation probability of a *de novo* protein

As a final example, we showcase how the combination with Rosetta's structure-based design toolkit enables the optimization of Rosetta score as well as the predicted modification probability (Fig 5). As the PTM prediction models are implemented as SimpleMetric (in Rosetta, a module for measuring a property of a structure) they can readily be used as objective of a Monte Carlo optimization protocol. As test case, we focused on the *de novo* serine-kinase driven phosphorylation switch from Woodall et al. [44] (Fig 5A). To improve the predicted modification probability of a given site, we randomly mutated the neighborhood of the key residue, accepting/rejecting the mutation based on whether it improved the total score, as well as the predicted probability (Fig 5B). We analyzed the predicted phosphorylation of the introduced phosphorylation sites, correctly predicting them as phosphorylated and all other Ser/



**Fig 4. Using structure-based modeling to predict experimentally verified glycosylation sites in influenza hemagglutinin.** A). Hemagglutinin structure of the H3N2 Hongkong 1968 (HK 68) influenza strain (PDB ID: 4FNK) with *N*-linked glycosylation sites visualized through Rosetta glycan modeling (blue). B) *N*-linked glycosylation sites (orange) of later observed influenza strains threaded onto the original HK 68 structure using structure-based modeling. C) Predicted glycosylation probabilities of known *N*-linked glycosylation sites from the early HK 68 strain (blue) or later observed strains (orange) which were modeled onto the HK 68 structure. The prediction threshold of 0.5 is shown as a gray dotted line.


<https://doi.org/10.1371/journal.pcbi.1011939.g004>

Thr residues as unphosphorylated, with site S93 having the lowest predicted probability of the four introduced sites (Fig 5C). Next, we used the Monte Carlo optimization protocol to improve the predicted probability of the phosphorylation site S93, designing a triple mutation (I89R, A92T, Q97R) which showed an improvement in predicted probability from 0.63 to 0.88 (Fig 5D).

## Discussion

In this work, we combined machine learning with structure-based protein design to predict and (re-)engineer PTMs in proteins. Our main result is that this combination of accurate prediction and design allows the modification of the predicted rate of PTMs occurring in proteins. We were able to predict PTM probabilities not only on native structures, but also on structures altered with Rosetta design. Interestingly, combining the prediction of certain PTMs with the prediction of other modifications increased performance for multiple cases. To do so, we pooled data for PTMs with unique modified amino acids (for example only one kind of lysine modification) and switched to a multi-class classification setting. Additionally, as this increased the number of examples for training, we added a small attention-based layer to our sequence track which is also responsible for the better performance. The improvement was especially prominent for cases with few or unbalanced data. Our initial reasoning for combining different modifications was that the surroundings of a PTM site should share a similar feature space as, e.g., a potential site must be exposed to enable enzyme binding.

In the case of Protein A deamidation, we correctly predicted the susceptibility of four out of five asparagine residues. Additionally, we could show that using Rosetta structural modelling in combination with modification prediction was able to recapitulate changes in deamidation probability. For asparagine at position 28, a mutation of its neighbor from glycine to alanine



**Fig 5. Optimizing the predicted phosphorylation probability of a *de novo* protein using structure-based design.** A). Structure of the *de novo* serine-kinase driven protein switch from Woodall et al. [44]; originally introduced phosphorylation sites are colored red. Mutations predicted to improve the phosphorylation probability of site S93 are colored in yellow. B) Monte Carlo optimization protocol using the GenericMonteCarloMover, starting from the original protein structure, randomly mutating a neighborhood residue of the phosphorylation site, and then accepting or rejecting the mutation based on the Rosetta total score (using a Metropolis criterion to avoid local minima) and predicted phosphorylation probability. This inner loop is repeated 50 times and the pose with the highest phosphorylation probability is output. C) Predicted phosphorylation probabilities of sites introduced by Woodall et al. [44](red) and other Ser/Thr residues found in the *de novo* protein. The prediction threshold of 0.5 is shown as a gray dotted line. D) Results of the Monte Carlo optimization protocol for phosphorylation site S93, showing the predicted phosphorylation probability versus the Rosetta total score for 1000 trajectories. The original design is marked as red square and the best design (highest predicted phosphorylation probability) is marked as yellow star. The Rosetta score and predicted phosphorylation probability of the original design is highlighted as blue and yellow dotted line, respectively.

<https://doi.org/10.1371/journal.pcbi.1011939.g005>

resulted in a drastically reduced deamidation probability, which is confirmed by previous experimental data [69]. In the case of influenza hemagglutinin, we were able to correctly predict four out of five glycosylation sites of the early H3N2 HK68 strain and three out of four later acquired glycosylation sites by modifying the structure of the original strain. One reason for the misclassified positions could be the inadequate modeling of the mutated backbone, which prevents accurate prediction. For the *de novo* serine-kinase driven phosphorylation switch from Woodall et al. [44] we accurately predicted the four introduced phosphorylation sites and used a Monte Carlo based optimization protocol to find mutations that increased the predicted phosphorylation probability of site S93 from 0.63 to 0.88. The best design had a Q97R mutation at the n+4 site which is in line with previous characterization of protein kinase A preferences [74]. Effective phosphorylation should increase the extent of activation in the presence of kinase and is therefore likely to improve the dynamic range of the protein switch. Taken together, these results show promise for accurate prediction not only of native, but also of designed and/or modeled proteins. As the field of PTM engineering grows more cases should become available to build a test set that goes beyond the case studies presented here. To facilitate thorough testing, a shift to also publish negative data for failed PTM engineering examples will be necessary. Additionally, we did not experimentally validate the resulting mutations of our case studies, as such a verification should test a broad set of proteins for one

PTM, something that is out of scope of the current work that focuses on the prediction and engineering of many modifications. Overall, it must be pointed out that our method presented here is very challenging to benchmark, as appropriate data are not necessarily available, especially for protein design tasks. We foresee that as more data become available, our method would require updates and retraining.

Multiple other studies have worked on predicting PTMs [46,75,76,77], mainly focusing on one modification using sequence data. Here, in addition to sequence information, we leveraged the power of AlphaFold2 to enrich our features with structural data. In the case of *N*-linked glycosylation, some studies have not limited themselves to the NxT/S sequon and therefore achieve higher accuracies on their data sets [45]. Similarly, a recent study on predicting *N*-linked glycosylation used proteins that were known to be localized in the cell nucleus (and therefore never glycosylated) as negative examples [46]. While the prediction of cellular localization of proteins is interesting, this would not translate to designing new glycosylation sites. A noteworthy exception is an earlier study [78] which also used a stringent filtering approach to select positive and negative sequons based on the PDB, showing that a combination of structure and sequence features was superior to sequence features alone. Since this study was published in 2012, the number of glycosylated proteins in the Protein Data Bank has steadily increased and we showed that new progress in the field of natural language processing and the combined prediction with other PTMs further increases the prediction performance.

A limitation of our study is the quality of structures predicted with AlphaFold2. While we filtered for local and overall pLDDT, the accuracy of all predicted structural models is not guaranteed. Additionally, it has been shown that regions with low AlphaFold2 pLDDT can correlate with intrinsically disordered regions (IDRs) [79] which are known to be enriched modifications like phosphorylation or *O*-linked glycosylation [80,81]. By removing protein models with low pLDDT we might have biased our prediction for areas with well-defined secondary structure. However, the distinction between intrinsically disordered regions and low-quality regions is not possible with pLDDT alone. While this limits prediction of PTMs for IDRs it reflects the engineering use case for which the tool was created. Engineering IDRs is an exciting future prospect that will be enabled by accurate prediction of such regions.

An important caveat of this work, especially in the context of lower prediction performance for some PTMs, is the focus on PTM-aware protein engineering. We base our prediction on the local context of a potentially modified site to generalize beyond natural proteins. As the lower accuracies for some modifications highlight, our models are not intended to e.g., screen a whole proteome for glycosylation sites as models that consider homology would probably achieve higher accuracies. Instead, we focus on the downstream task of engineering particular modifications for which we optimized our prediction models, and we argue that this provides practically useful tools for protein engineering tasks. While our method allows the prediction of modifications irrelevant of protein homology or other global features like cellular localization, it therefore requires the user to be informed about the to-be engineered protein. For example, optimizing the probability of an *N*-linked glycosylation site will still not result in a glycosylated protein if the protein lacks a secretion tag or is expressed in an unsuitable system like *Escherichia coli*.

In the case of *N*-linked glycosylation, a major limitation is the availability of high-quality data. While we extensively curated our dataset, including cross-referencing UniProt data and manually checking electron densities, false negative sequons could still be present when electron densities were missing and UniProt annotations not available. One option to supplement PTMs with low data availability would have been to leverage enzyme profiling data which are available for e.g., *O*- and *N*-glycosyltransferases [82]. However, the profiling studies are based on analyzing short peptides independent from proteins, which provides information of enzyme specificity in an idealized system. Using this kind of data would therefore prevent us

from using certain features calculated from protein structures, like solvent-accessible-surface-area (SASA). Additionally, taking the example of *N*-linked glycosylation, modification is far from being based on substrate recognition alone, as is shown by the preferences for loops over structured residue sites. Training models with substrate recognition data could therefore, especially in the case of PTMs with low data availability, lead to models unable to accurately predict a modification in its full protein structure context. As we think that this would be a major limitation in our downstream engineering task, we choose to limit ourselves to determined, or predicted, protein structures. To achieve better performance, data on sequons that are not occupied will be necessary, as most databases focus on positive examples.

## Conclusion

The combination of accurate prediction and structure-based design should enable the modification of existing, as well as the introduction of novel, PTMs. The potential applications of our work include, but are not limited to, glycan masking epitopes, strengthening protein-protein interactions through phosphorylation, designing PTM-dependent protein switches, as well as protecting proteins from deamidation liabilities. In conclusion, our work adds novel tools to Rosetta's protein engineering toolbox, that allow for the rational design of PTMs.

## Methods

### Collection of proteins with PTMs

We first collected experimentally verified modifications sites from the dbPTM non-homologous benchmark dataset [61,62]. To enrich our features with structural data, we additionally used the AlphaFold2 database to download a predicted model for each protein in the dataset, filtering the models by local and overall pLDDT greater than 50. While the benchmark present in the dbPTM is already non-homologous, we clustered the sequence windows surrounding a potentially modified site (10 residues) to 90% sequence identity with CD-HIT [83] to further avoid redundancy. We calculated the SASA, dihedral angles and secondary structure for all remaining proteins using PyRosetta [63]. This procedure was done for all PTMs except for *N*-linked glycosylation and deamidation. In the case of *N*-linked glycosylation, no benchmark comparing occupied and unoccupied sequons was readily available. Therefore, we collected all eukaryotic proteins from the Protein Data Bank [64] with at least one *N*-linked glycosylation site present and searched them for additional unoccupied sequons. Next, we cross-checked potential negative sites against UniProt annotations [65,66] and removed any that were annotated as experimentally verified to be glycosylated. To further avoid false negatives, we manually checked the electron densities of all potential negatives and excluded all with ambiguous densities. As the last step we clustered the sequence identities of the sequence windows to 90% using CD-HIT. In the case of deamidation, the largest dataset available is from Delmar et al [67], however, no full sequences were published or shared on request, therefore the dataset was used without protein structure prediction or feature calculation in PyRosetta. All datasets and detailed scripts can be found at [github.com/MeilerLab/PTMPrediction](https://github.com/MeilerLab/PTMPrediction).

### Training of a two-track neural network to predict PTMs

We trained a two-track neural network using Tensorflow and Keras [58,84] using 10-fold cross validation through Sklearn [85] and different sampling strategies using imbalanced-learn [86]. We oversampled the positive class for all PTMs, except for phosphorylation and *O*-linked glycosylation where we under sampled the negative classes, resulting in both cases in a 1:1 ratio of negative and positive cases. Additionally, numpy [87], pandas [88,89], matplotlib [90]

and seaborn [91] were used for data preparation and plotting. The first track of our neural network uses a sequence window of eight residues (-4/+4 around modification) as input into an embedding layer, followed by a global average pooling layer and a dense layer. The second track uses phi/psi angles of the potentially modified residue and its two neighbors, as well as the secondary structure and SASA of the potentially modified residue as input into two fully connected dense layers. The two-tracks were concatenated into one dense layer with a sigmoidal activation function outputting a probability between zero and one. In the case of training on multiple modification predictions, we added a small attention layer after the embedding layer to the sequence track, an additional fully connected dense layer to the structure track and changed the output layer to a softmax activation function (Fig 2). For the optimization we used Adam with a learning rate of 0.0001 and trained for 200 epochs with early stopping. For the multi class training we additionally used a learning rate warmup with cosine decay. A binary cross-entropy loss was applied for the single models and a sparse categorical cross-entropy loss for the multi class approach. A script to reproduce the training can be found at [github.com/MeilerLab/PTMPrediction](https://github.com/MeilerLab/PTMPrediction).

### Incorporation of the neural network into Rosetta

To enable rapid combination with existing design and analysis methods in Rosetta, we incorporated our prediction method as a RosettaScripts [92] element. RosettaScripts enables the rapid and flexible combination of existing protocols without proficiency in C++/Python. Therefore, we implemented feature calculation and interference in a Rosetta SimpleMetric (a module for measuring properties of a Pose) called the PTMPredictionMetric using the newly developed RosettaTensorflowManager. Full details are in [S1 Text](#). Exemplary protocols to compile Rosetta with the required submodules, how to run PTM prediction and PTM design are deposited at [github.com/MeilerLab/PTMPrediction](https://github.com/MeilerLab/PTMPrediction).

### Deamidation rate prediction of Protein A

We collected the structure of Protein A from the Protein Data Bank (ID: 1DEE [68]) and relaxed it using FastRelax [93,94] in RosettaScripts [92]. Afterwards we predicted the deamidation probability for each asparagine using the newly developed PTMPredictionMetric which uses the described neural net. A script for this task can be found at [github.com/MeilerLab/PTMPrediction](https://github.com/MeilerLab/PTMPrediction). Next, we used FastDesign [95] to mutate the neighbor of N23 and N28 to all possible amino acids except cysteine and then repeated our deamidation rate prediction. ChimeraX was used to visualize the structures [96].

### Glycosylation prediction of influenza hemagglutinin

For prediction of influenza hemagglutinin *N*-linked glycosylation we first removed any ligands/glycans of the H3N2 HK68 strain (PDB ID: 4FNK [71]) and relaxed the structure using FastRelax [93,94]. We then predicted the glycosylation sites of the already present sequons using the newly developed PTMPredictionMover. Next, we introduced the sequons (including residues -2/+2) of glycosylation sites from newer strains into the original HK68 structure using Rosetta FastDesign [95], configured with a resfile specifying the particular mutations (*i.e.* with a fully determined sequence), and predicted their glycosylation probability. For visualization, the SimpleGlycosylateMover [54] was used to glycosylate *N*-linked glycosylation sites, and ChimeraX was used to render the resulting structures [96]. Scripts for prediction of glycosylation can be found at [github.com/MeilerLab/PTMPrediction](https://github.com/MeilerLab/PTMPrediction).

## Monte Carlo optimization of a *de novo* serine-kinase driven protein switch

First, we relaxed the modeled structure of pGFP-S4 from Woodall et al. [44] using FastRelax [82,83]. Next, we predicted the phosphorylation probability of all Ser/Thr residues using the newly developed PTMPredictionMover. We then created a custom RosettaScripts script incorporating the GenericMonteCarloMover to optimize the predicted probability of the phosphorylation site S93. Starting from the initial structure we randomly mutated a neighbor residue (positions 89, 92, 94, 95, 96 or 97) to any amino acid except cysteine and then accepted or rejected the mutation based on whether it improved Rosetta total score and predicted phosphorylation probability, repeating this for 50 trials in one trajectory. Using this protocol, 1000 designs were created and ranked by improvements in total score and predicted phosphorylation probability. Scripts for the prediction and design can be found at [github.com/MeilerLab/PTMPrediction](https://github.com/MeilerLab/PTMPrediction).

## Supporting information

**S1 Text. Table A in S1 Text.** Classes implemented for running Tensorflow models in Rosetta. **Table B in S1 Text.** Classes implemented to support the PTMPredictionMetric. **Table C in S1 Text.** Summary of positive and negative examples for each PTM type (DOCX)

## Acknowledgments

Computations for this work were done (in part) using resources of the Leipzig University Computing Centre.

## Author Contributions

**Conceptualization:** Moritz Ertelt, Jens Meiler, Clara T. Schoeder.

**Data curation:** Moritz Ertelt.

**Formal analysis:** Moritz Ertelt.

**Funding acquisition:** Jens Meiler, Clara T. Schoeder.

**Investigation:** Moritz Ertelt.

**Methodology:** Moritz Ertelt, Torben Schiffner, Jens Meiler, Clara T. Schoeder.

**Project administration:** Moritz Ertelt, Clara T. Schoeder.

**Resources:** Jens Meiler, Clara T. Schoeder.

**Software:** Moritz Ertelt, Vikram Khipple Mulligan, Jack B. Maguire, Sergey Lyskov, Rocco Moretti.

**Supervision:** Vikram Khipple Mulligan, Torben Schiffner, Jens Meiler, Clara T. Schoeder.

**Validation:** Moritz Ertelt.

**Visualization:** Moritz Ertelt.

**Writing – original draft:** Moritz Ertelt, Vikram Khipple Mulligan, Torben Schiffner, Jens Meiler, Clara T. Schoeder.

**Writing – review & editing:** Moritz Ertelt, Vikram Khipple Mulligan, Torben Schiffner, Jens Meiler, Clara T. Schoeder.

## References

1. Walsh G. Post-translational modifications of protein biopharmaceuticals. *Drug Discovery Today* 2010; 15:773–780. <https://doi.org/10.1016/j.drudis.2010.06.009> PMID: 20599624
2. Schwarz F, Aebi M. Mechanisms and principles of N-linked protein glycosylation. *Current Opinion in Structural Biology* 2011; 21:576–582. PMID: 21978957
3. Hart GW, Haltiwanger RS, Holt GD, Kelly WG. Nucleoplasmic and cytoplasmic glycoproteins. In *Ciba Foundation Symposium 145-Carbohydrate Recognition in Cellular Function: Carbohydrate Recognition in Cellular Function: Ciba Foundation Symposium 145*; 2007, 102–18.
4. Shental-Bechor D, Levy Y. Effect of glycosylation on protein folding: a close look at thermodynamic stabilization. *Proceedings of the National Academy of Sciences of the United States of America* 2008; 105:8256–8261. <https://doi.org/10.1073/pnas.0801340105> PMID: 18550810
5. Shakin-Eshleman SH, Spitalnik SL, Kasturi L. The Amino Acid at the X Position of an Asn-X-Ser Sequon Is an Important Determinant of N-Linked Core-glycosylation Efficiency. *The Journal of Biological Chemistry* 1996; 271:6363–6366. <https://doi.org/10.1074/jbc.271.11.6363> PMID: 8626433
6. Petrescu AJ, Milac AL, Petrescu SM, Dwek RA, Wormald MR. Statistical analysis of the protein environment of N-glycosylation sites: implications for occupancy, structure, and folding. *Glycobiology* 2004; 14:103–114. PMID: 14514716
7. Huang YW, Yang HI, Wu YT, Hsu TL, Lin TW, Kelly JW, et al. Residues comprising the enhanced aromatic sequon influence protein N-glycosylation efficiency. *Journal of the American Chemical Society* 2017; 139:12947–12955. <https://doi.org/10.1021/jacs.7b03868> PMID: 28820257
8. Wilson IB, Gavel Y, Von Heijne G. Amino acid distributions around O-linked glycosylation sites. *The Biochemical Journal* 1991; 275:529–534. <https://doi.org/10.1042/bj2750529> PMID: 2025231
9. Solá RJ, Griebenow KAI. Effects of glycosylation on the stability of protein pharmaceuticals. *Journal of Pharmaceutical Sciences* 2009; 98:1223–1245. <https://doi.org/10.1002/jps.21504> PMID: 18661536
10. Solá RJ, Griebenow K. Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy. *BioDrugs* 2010; 24:9–21. <https://doi.org/10.2165/11530550-000000000-00000> PMID: 20055529
11. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. *Nature Reviews. Drug Discovery* 2009; 8:226–234. <https://doi.org/10.1038/nrd2804> PMID: 19247305
12. Sundaram PV, Venkatesh R. Retardation of thermal and urea induced inactivation of alpha-chymotrypsin by modification with carbohydrate polymers. *Protein Engineering* 1998; 11:699–705. <https://doi.org/10.1093/protein/11.8.699> PMID: 9749923
13. Solá RJ, Al-Azzam W, Griebenow K. Engineering of protein thermodynamic, kinetic, and colloidal stability: Chemical glycosylation with monofunctionally activated glycans. *Biotechnology and Bioengineering* 2006; 94:1072–1079. <https://doi.org/10.1002/bit.20933> PMID: 16586505
14. Baudyš M, Uchio T, Mix D, Kim SW, Wilson D. Physical stabilization of insulin by glycosylation. *Journal of Pharmaceutical Sciences* 1995; 84:28–33. <https://doi.org/10.1002/jps.2600840108> PMID: 7714739
15. Nissen C. Glycosylation of recombinant human granulocyte colony stimulating factor: implications for stability and potency. *European Journal of Cancer* 1994; 30:12–14. PMID: 7535065
16. Oh-Eda M, Hasegawa M, Hattori K, Kuboniwa H, Kojima T, Orita T, et al. O-linked sugar chain of human granulocyte colony-stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity. *The Journal of Biological Chemistry* 1990; 265:11432–11435. PMID: 1694845
17. Ono M. Physicochemical and biochemical characteristics of glycosylated recombinant human granulocyte colony stimulating factor (lenograstim). *European Journal of Cancer* 1994; 30:7–11.
18. Ni H, Blajchman MA, Ananthanarayanan VS, Smith IJ, Sheffield WP. Mutation of any site of N-linked glycosylation accelerates the in vivo clearance of recombinant rabbit antithrombin. *Thrombosis Research* 2000; 99:407–415. [https://doi.org/10.1016/s0049-3848\(00\)00263-2](https://doi.org/10.1016/s0049-3848(00)00263-2) PMID: 10963791
19. Barbey F, Hayoz D, Widmer U, Burnier M. Efficacy of enzyme replacement therapy in Fabry disease. *Current Medicinal Chemistry* 2004; 2:277–286.
20. Beck M. Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safety. *Expert Opinion on Biological Therapy* 2009; 9:255–261. <https://doi.org/10.1517/14712590802658428> PMID: 19236256
21. Lee K, Jin X, Zhang K, Copertino L, Andrews L, Baker-Malcolm J, et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. *Glycobiology* 2003; 13:305–313. <https://doi.org/10.1093/glycob/cwg034> PMID: 12626384
22. Duan H, Chen X, Boyington JC, Cheng C, Zhang Y, Jafari AJ, et al. Glycan masking focuses immune responses to the HIV-1 CD4-binding site and enhances elicitation of VRC01-class precursor antibodies. *Immunity* 2018; 49:301–311. <https://doi.org/10.1016/j.immuni.2018.07.005> PMID: 30076101



23. Sesterhenn F, Bonet J, Correia BE. Structure-based immunogen design—leading the way to the new age of precision vaccines. *Current Opinion in Structural Biology* 2018; 51:163–169. <https://doi.org/10.1016/j.sbi.2018.06.002> PMID: 29980105
24. Eggink D, Goff PH, Palese P. Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain. *Journal of Virology* 2014; 88:699–704. <https://doi.org/10.1128/JVI.02608-13> PMID: 24155380
25. Robinson NE, Robinson AB. Deamidation of human proteins. *Proceedings of the National Academy of Sciences of the United States of America* 2001; 98:12409–12413. <https://doi.org/10.1073/pnas.221463198> PMID: 11606750
26. Robinson NE. Protein deamidation. *Proceedings of the National Academy of Sciences of the United States of America* 2002; 99:5283–5288. <https://doi.org/10.1073/pnas.082102799> PMID: 11959979
27. Robinson NE, Robinson A. *Molecular clocks: deamidation of asparaginyl and glutaminyl residues in peptides and proteins*. Althouse press; 2004.
28. Robinson NE, Robinson AB. Prediction of protein deamidation rates from primary and three-dimensional structure. *Proceedings of the National Academy of Sciences of the United States of America* 2001; 98:4367–4372. <https://doi.org/10.1073/pnas.071066498> PMID: 11296285
29. Robinson NE, Robinson AB. Prediction of primary structure deamidation rates of asparaginyl and glutaminyl peptides through steric and catalytic effects. *The Journal of Peptide Research* 2004; 63:437–448. <https://doi.org/10.1111/j.1399-3011.2004.00148.x> PMID: 15140161
30. Gervais D. Protein deamidation in biopharmaceutical manufacture: understanding, control and impact. *Journal of Chemical Technology and Biotechnology* 2016; 91:569–575.
31. Irudayanathan FJ, Zarzar J, Lin J, Izadi S. Divining Deamidation and Isomerization in Therapeutic Proteins: Effect of Neighboring Residue. *bioRxiv*. 2021.
32. Lu X, Nobrega RP, Lynaugh H, Jain T, Barlow K, Boland T, et al. Deamidation and isomerization liability analysis of 131 clinical-stage antibodies. In *MAbs*. 2019:45–57. <https://doi.org/10.1080/19420862.2018.1548233> PMID: 30526254
33. Moss CX, Matthews SP, Lamont DJ, Watts C. Asparagine deamidation perturbs antigen presentation on class II major histocompatibility complex molecules. *The Journal of Biological Chemistry* 2005; 280:18498–18503. <https://doi.org/10.1074/jbc.M501241200> PMID: 15749706
34. Verma A, McNichol B, et al. Use of site-directed mutagenesis to model the effects of spontaneous deamidation on the immunogenicity of Bacillus anthracis protective antigen. *Infection and Immunity* 2013; 81:278–284. <https://doi.org/10.1128/IAI.00863-12> PMID: 23115046
35. Verma A, Ngundi MM, Burns DL. Mechanistic analysis of the effect of deamidation on the immunogenicity of anthrax protective antigen. *Clinical and Vaccine Immunology* 2016; 23:396–402. <https://doi.org/10.1128/CVI.00701-15> PMID: 26912784
36. Joshi AB, Kirsch LE. The relative rates of glutamine and asparagine deamidation in glucagon fragment 22–29 under acidic conditions. *Journal of Pharmaceutical Sciences* 2002; 91:2332–2345. <https://doi.org/10.1002/jps.10213> PMID: 12379918
37. Giles AR, Sims JJ, Turner KB, Govindasamy L, Alvira MR, Lock M, et al. Deamidation of amino acids on the surface of adeno-associated virus capsids leads to charge heterogeneity and altered vector function. *Molecular Therapy* 2018; 26:2848–2862. <https://doi.org/10.1016/j.ymthe.2018.09.013> PMID: 30343890
38. Goolcharran C, Jones AJS, Borchardt RT. Comparison of the rates of deamidation, diketopiperazine formation, and oxidation in recombinant human vascular endothelial growth factor and model peptides. *AAPS PharmSci* 2000; 2:42–47. <https://doi.org/10.1208/ps020105> PMID: 11741221
39. Bing SJ, Justesen S, Wu WW, Sajib AM, Warrington S, Baer A, et al. Differential T cell immune responses to deamidated adeno-associated virus vector. *Molecular Therapy—Methods & Clinical Development* 2022; 24:255–267. <https://doi.org/10.1016/j.omtm.2022.01.005> PMID: 35211638
40. Scheuermann MJ, Forbes CR, Zondlo NJ. Redox-responsive protein design: Design of a small protein motif dependent on glutathionylation. *Biochemistry* 2018; 57:6956–6963. <https://doi.org/10.1021/acs.biochem.8b00973> PMID: 30511831
41. Gao F, Thornley BS, Tressler CM, Naduthambi D, Zondlo NJ. Phosphorylation-dependent protein design: design of a minimal protein kinase-inducible domain. *Organic & Biomolecular Chemistry* 2019; 17:3984–3995. <https://doi.org/10.1039/c9ob00502a> PMID: 30942803
42. Winter DL, Iranmanesh H, Clark DS, Glover DJ. Design of tunable protein interfaces controlled by post-translational modifications. *ACS Synthetic Biology* 2020; 9:2132–2143. <https://doi.org/10.1021/acssynbio.0c00208> PMID: 32702241
43. Thompson HF, Beesley JL, Langlands HD, Edgell CL, Savery NJ, Woolfson DN. Rational Design of Phosphorylation-Responsive Coiled Coil-Peptide Assemblies. *ACS Synthetic Biology* 2023; 12:1308–1319. <https://doi.org/10.1021/acssynbio.3c00064> PMID: 36988263

44. Woodall NB, Weinberg Z, Park J, Busch F, Johnson RS, Feldbauer MJ, et al. De novo design of tyrosine and serine kinase-driven protein switches. *Nature Structural & Molecular Biology* 2021; 28:762–770. <https://doi.org/10.1038/s41594-021-00649-8> PMID: 34518698
45. Akmal MA, Rasool N, Khan YD. Prediction of N-linked glycosylation sites using position relative features and statistical moments. *PLoS One* 2017; 12:e0181966. <https://doi.org/10.1371/journal.pone.0181966> PMID: 28797096
46. Pakhrin SC, Aoki-Kinoshita KF, Caragea D, Kc DB, others. DeepNGlyPred: A Deep Neural Network-Based Approach for Human N-Linked Glycosylation Site Prediction. *Molecules* 2021; 26: 7314. <https://doi.org/10.3390/molecules26237314> PMID: 34885895
47. Taherzadeh G, Dehzangi A, Golchin M, Zhou Y, Campbell MP. SPRINT-Gly: predicting N-and O-linked glycosylation sites of human and mouse proteins by using sequence and predicted structural properties. *Bioinformatics* 2019; 35:4140–4146. <https://doi.org/10.1093/bioinformatics/btz215> PMID: 30903686
48. Pitti T, Chen CT, Lin HN, Choong WK, Hsu WL, Sung TY. N-GlyDE: a two-stage N-linked glycosylation site prediction incorporating gapped dipeptides and pattern-based encoding. *Scientific Reports* 2019; 9:15975. <https://doi.org/10.1038/s41598-019-52341-z> PMID: 31685900
49. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. *Nature* 2021; 596:583–589. <https://doi.org/10.1038/s41586-021-03819-2> PMID: 34265844
50. Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G, et al. AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. *Nucleic Acids Research* 2022; 50:D439–D444. <https://doi.org/10.1093/nar/gkab1061> PMID: 34791371
51. Leaver-Fay A, Tyka M, Lewis SM, Lange OF, Thompson J, Jacak R, et al. ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. *Methods in Enzymology* 2011:545–574. <https://doi.org/10.1016/B978-0-12-381270-4.00019-6> PMID: 21187238
52. Kuhlman B, Dantas G, Ireton GC, Varani G, Stoddard BL, Baker D. Design of a novel globular protein fold with atomic-level accuracy. *Science* 2003; 302:1364–1368. <https://doi.org/10.1126/science.1089427> PMID: 14631033
53. Richter F, Leaver-Fay A, Khare SD, Bjelic S, Baker D. De novo enzyme design using Rosetta3. *PLoS One* 2011; 6:e19230. <https://doi.org/10.1371/journal.pone.0019230> PMID: 21603656
54. Adolf-Bryfogle J, Labonte JW, Kraft JC, Shapovalov M, Raemisch S, Lütke T, et al. Growing Glycans in Rosetta: Accurate de novo glycan modeling, density fitting, and rational sequon design. *Biorxiv*. 2021:2021–2009.
55. Labonte JW, Adolf-Bryfogle J, Schief WR, Gray JJ. Residue-centric modeling and design of saccharide and glycoconjugate structures. *Journal of Computational Chemistry* 2017; 38:276–287. <https://doi.org/10.1002/jcc.24679> PMID: 27900782
56. Nance ML, Labonte JW, Adolf-Bryfogle J, Gray JJ. Development and Evaluation of GlycanDock: A Protein–Glycoligand Docking Refinement Algorithm in Rosetta. *The Journal of Physical Chemistry. B* 2021, 125, 25: 6807–20. <https://doi.org/10.1021/acs.jpcc.1c00910> PMID: 34133179
57. Mulligan VK. Current directions in combining simulation-based macromolecular modeling approaches with deep learning. *Expert Opinion on Drug Discovery* 2021; 16:1025–1044. <https://doi.org/10.1080/17460441.2021.1918097> PMID: 33993816
58. Abadi M, Agarwal A, Barham P, Brevdo E, Chen Z, Citro C, et al. TensorFlow: Large-Scale Machine Learning on Heterogeneous Systems. 2015. Software available from [tensorflow.org](https://www.tensorflow.org).
59. Koehler Leman J, Lyskov S, Lewis SM, Adolf-Bryfogle J, Alford RF, Barlow K, et al. Ensuring scientific reproducibility in bio-macromolecular modeling via extensive, automated benchmarks. *Nature Communications* 2021; 12:6947. <https://doi.org/10.1038/s41467-021-27222-7> PMID: 34845212
60. Kern F, Fehlmann T, Keller A. On the lifetime of bioinformatics web services. *Nucleic Acids Research* 2020; 48:12523–12533. <https://doi.org/10.1093/nar/gkaa1125> PMID: 33270886
61. Huang KY, Lee TY, Kao HJ, Ma CT, Lee CC, Lin TH, et al. dbPTM in 2019: exploring disease association and cross-talk of post-translational modifications. *Nucleic Acids Research* 2019; 47:D298–D308. <https://doi.org/10.1093/nar/gky1074> PMID: 30418626
62. Li Z, Li S, Luo M, Jhong JH, Li W, Yao L, et al. dbPTM in 2022: an updated database for exploring regulatory networks and functional associations of protein post-translational modifications. *Nucleic Acids Research* 2022; 50:D471–D479. <https://doi.org/10.1093/nar/gkab1017> PMID: 34788852
63. Chaudhury S, Lyskov S, Gray JJ. PyRosetta: a script-based interface for implementing molecular modeling algorithms using Rosetta. *Bioinformatics* 2010; 26:689–691. <https://doi.org/10.1093/bioinformatics/btq007> PMID: 20061306

64. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The protein data bank. *Nucleic Acids Research* 2000; 28:235–242. <https://doi.org/10.1093/nar/28.1.235> PMID: 10592235
65. UniProt: the Universal Protein knowledgebase in 2023. *Nucleic Acids Research* 2023; 51:D523–D531. <https://doi.org/10.1093/nar/gkac1052> PMID: 36408920
66. Farriol-Mathis N, Garavelli JS, Boeckmann B, Duvaud S, Gasteiger E, Gateau A, et al. Annotation of post-translational modifications in the Swiss-Prot knowledge base. *Proteomics* 2004; 4:1537–1550. <https://doi.org/10.1002/pmic.200300764> PMID: 15174124
67. Delmar JA, Wang J, Choi SW, Martins JA, Mikhail JP. Machine learning enables accurate prediction of asparagine deamidation probability and rate. *Molecular Therapy—Methods & Clinical Development* 2019; 15:264–274. <https://doi.org/10.1016/j.omtm.2019.09.008> PMID: 31890727
68. Graille M, Stura EA, Corper AL, Sutton BJ, Taussig MJ, Charbonnier JB, et al. Crystal structure of a *Staphylococcus aureus* protein A domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity. *Proceedings of the National Academy of Sciences of the United States of America* 2000; 97:5399–5404. <https://doi.org/10.1073/pnas.97.10.5399> PMID: 10805799
69. Linhult M, Gülich S, Gräslund T, Simon A, Karlsson M, Sjöberg A, et al. Improving the tolerance of a protein analogue to repeated alkaline exposures using a bypass mutagenesis approach. *Proteins* 2004; 55:407–416. <https://doi.org/10.1002/prot.10616> PMID: 15048831
70. Wiley DC, Wilson IA, Skehel JJ. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. *Nature* 1981; 289:373–378. <https://doi.org/10.1038/289373a0> PMID: 6162101
71. Ekiert DC, Kashyap AK, Steel J, Rubrum A, Bhabha G, Khayat R, et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop. *Nature* 2012; 489:526–532. <https://doi.org/10.1038/nature11414> PMID: 22982990
72. Suzuki Y. Positive selection for gains of N-linked glycosylation sites in hemagglutinin during evolution of H3N2 human influenza A virus. *Genes & Genetic Systems* 2011; 86:287–294. <https://doi.org/10.1266/ggs.86.287> PMID: 22362027
73. Alymova IV, York IA, Air GM, Cipollo JF, Gulati S, Baranovich T, et al. Glycosylation changes in the globular head of H3N2 influenza hemagglutinin modulate receptor binding without affecting virus virulence. *Scientific Reports* 2016; 6:1–15.
74. Huttu JE, Jarrell ET, Chang JD, Abbott DW, Storz P, Toker A, et al. A rapid method for determining protein kinase phosphorylation specificity. *Nature Methods* 2004; 1:27–29. <https://doi.org/10.1038/nmeth708> PMID: 15782149
75. Luo F, Wang M, Liu Y, Zhao XM, Li A. DeepPhos: prediction of protein phosphorylation sites with deep learning. *Bioinformatics* 2019; 35:2766–2773. <https://doi.org/10.1093/bioinformatics/bty1051> PMID: 30601936
76. Chen YZ, Wang ZZ, Wang Y, Ying G, Chen Z, Song J. nhKcr: a new bioinformatics tool for predicting crotonylation sites on human nonhistone proteins based on deep learning. *Briefings in Bioinformatics* 2021; 22:bbab146. <https://doi.org/10.1093/bib/bbab146> PMID: 34002774
77. Hasan MM, Manavalan B, Khatun MS, Kurata H. Prediction of S-nitrosylation sites by integrating support vector machines and random forest. *Molecular Omics* 2019; 15:451–458. <https://doi.org/10.1039/c9mo00098d> PMID: 31710075
78. Chuang GY, Boyington JC, Joyce MG, Zhu J, Nabel GJ, Kwong PD, et al. Computational prediction of N-linked glycosylation incorporating structural properties and patterns. *Bioinformatics* 2012; 28:2249–2255. <https://doi.org/10.1093/bioinformatics/bts426> PMID: 22782545
79. Ruff KM, Pappu RV. AlphaFold and implications for intrinsically disordered proteins. *Journal of Molecular Biology* 2021; 433:167208. <https://doi.org/10.1016/j.jmb.2021.167208> PMID: 34418423
80. Iakoucheva LM, Radivojac P, Brown CJ, O'Connor TR, Sikes JG, Obradovic Z, et al. The importance of intrinsic disorder for protein phosphorylation. *Nucleic Acids Research* 2004; 32:1037–1049. <https://doi.org/10.1093/nar/gkh253> PMID: 14960716
81. Prates ET, Guan X, Li Y, Wang X, Chaffey PK, Skaf MS, et al. The impact of O-glycan chemistry on the stability of intrinsically disordered proteins. *Chemical Science* 2018; 9:3710–3715. <https://doi.org/10.1039/c7sc05016j> PMID: 29780502
82. Kightlinger W, Lin L, Rosztoczy M, Li W, DeLisa MP, Mrksich M, et al. Design of glycosylation sites by rapid synthesis and analysis of glycosyltransferases. *Nature Chemical Biology* 2018; 14:627–635. <https://doi.org/10.1038/s41589-018-0051-2> PMID: 29736039
83. Fu L, Niu B, Zhu Z, Wu S, Li W. CD-HIT: accelerated for clustering the next-generation sequencing data. *Bioinformatics* 2012; 28:3150–3152. <https://doi.org/10.1093/bioinformatics/bts565> PMID: 23060610

84. Chollet F, et al. Keras. 2015. Github. Available from <https://github.com/keras-team/keras>.
85. Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. Scikit-learn: Machine Learning in Python. *Journal of Machine Learning Research* 2011; 12:2825–2830.
86. Lemaître G, Nogueira F, Aridas CK. Imbalanced-learn: A Python Toolbox to Tackle the Curse of Imbalanced Datasets in Machine Learning. *Journal of Machine Learning Research* 2017; 18:1–5.
87. Harris CR, Millman KJ, van der Walt SJ, Gommers R, Virtanen P, Cournapeau D, et al. Array programming with NumPy. *Nature* 2020 Sep; 585: 357–362. <https://doi.org/10.1038/s41586-020-2649-2> PMID: 32939066
88. McKinney W. Data Structures for Statistical Computing in Python. In van der Walt S, Millman J, editors. *Proceedings of the 9th Python in Science Conference*; 2010. 56–61.
89. The pandas development team. pandas-dev/pandas: Pandas. 2023 Jan. Zenodo. Available from <https://doi.org/10.5281/zenodo.3509134>.
90. Hunter JD. Matplotlib: A 2D graphics environment. *Computing in Science & Engineering* 2007; 9:90–95.
91. Waskom ML. seaborn: statistical data visualization. *J Open Source Software*. 2021; 6:3021.
92. Fleishman SJ, Leaver-Fay A, Corn JE, Strauch EM, Khare SD, Koga N, et al. RosettaScripts: a scripting language interface to the Rosetta macromolecular modeling suite. *PLoS One* 2011; 6:e20161. <https://doi.org/10.1371/journal.pone.0020161> PMID: 21731610
93. Tyka MD, Keedy DA, André I, DiMaio F, Song Y, Richardson DC, et al. Alternate states of proteins revealed by detailed energy landscape mapping. *Journal of Molecular Biology* 2011; 405:607–618. <https://doi.org/10.1016/j.jmb.2010.11.008> PMID: 21073878
94. Conway P, Tyka MD, DiMaio F, Konerding DE, Baker D. Relaxation of backbone bond geometry improves protein energy landscape modeling. *Protein Science* 2014; 23:47–55. <https://doi.org/10.1002/pro.2389> PMID: 24265211
95. Bhardwaj G, Mulligan VK, Bahl CD, Gilmore JM, Harvey PJ, Cheneval O, et al. Accurate de novo design of hyperstable constrained peptides. *Nature* 2016; 538:329–335. <https://doi.org/10.1038/nature19791> PMID: 27626386
96. Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. *Protein Science* 2021; 30:70–82. <https://doi.org/10.1002/pro.3943> PMID: 32881101